Option chain shows key data for Better For You Wellness's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Better For You Wellness.

Better For You Wellness (OTC:BFYW) Stock, Option Chain

Better For You Wellness Inc is engaged in building brands and companies organically as well as exploring and evaluating various opportunities in the plant-based and science-focused food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions.

Cannabis

News

Penny Stocks

Markets

BFYW

Ohio-based Better For You Wellness, Inc. (OTC: BFYW) announced on Tuesday the successful closure of its previously announced asset purchase

Popular Coffee Collection To Boost Ohio Wellness Company&#39;s Position In Market

Entrepreneurship

Retail Sales

Exclusives

General

AMZN

Better For You Wellness, Inc. (OTCQB: BFYW), an Ohio-based wellness company at the forefront of plant-based and science-driven innovations in the rapidly expanding $1.5 trillion wellness industry has entered into a binding Membership Interest Purchase Agreement (MIPA) with The Ideation Lab (TIL) LLC

EXCLUSIVE: Better For You Wellness To Acquire Ideation Lab, Jordre Well And Its Signature CBD Coffee Brand

Long Ideas

Insider Trades

Pre-Market Outlook

Trading Ideas

BRGC

The Dow Jones closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AIM ImmunoTech And 2 Other Stocks Under $1 Insiders Are Buying

BETTER FOR YOU WELLNESS by Better For You Wellness Inc.

Better For You Wellness Inc

-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110
-First participant dosing anticipated in the first quarter of 2025
-Interim readout expected in second half of 2025 and completion of Phase 1/2a study anticipated in 2026

Biotech

Health Care

KRRO

Korro Bio Has Received Approval From The Australian Bellberry Human Research Ethics Committee And Clearance From The Australian Therapeutic Goods Administration To Initiate A Phase 1/2a Study Of KRRO-110 For Alpha-1 Antitrypsin Deficiency

Rosenblatt analyst Catharine Trebnick upgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Neutral to Buy and raises the price target from $390 to $425.

Upgrades

Price Target

Analyst Ratings

PANW

Rosenblatt Upgrades Palo Alto Networks to Buy, Raises Price Target to $425

Keybanc analyst Jeffrey Hammond maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Overweight and raises the price target from $725 to $775.

Keybanc Maintains Overweight on Parker Hannifin, Raises Price Target to $775

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) hit a new all-time high of $98,310 on Thursday morning during European trading hours, he total net asset value of U.S. Bitcoin spot exchange-traded funds (ETFs) has exceeded $100 billion, a milestone achieved in just 10 months since their <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">launch in January</a>.
What Happened: Over the past three days, Bitcoin spot ETFs have seen $1.84 billion in net inflows, reflecting strong investor confidence. 
U.S.-based ETFs have contributed $29.4 billion in net flows this year, solidifying their role as a primary driver of capital into Bitcoin.
Nate Geraci, president of The ETF Store, <a href="https://x.com/NateGeraci/status/1859406924975845770">highlighted</a> on X the growing demand for spot ETFs and revealed that applications for funds linked to other digital assets, including Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), and Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>), are also in the pipeline.
Bitcoin reached $97,900 earlier this week before climbing to $98,310, supported by aggressive demand for long-dated call options and positive headlines about corporate adoption, according to QCP Capital.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42099670/core-fusion-upgrade-introduces-dual-staking-and-liquid-bitcoin-staking">Core Fusion Upgrade Introduces Dual Staking And Liquid Bitcoin Staking</a>
Why It Matters: Companies like MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) are fueling the bullish sentiment, with the firm raising $2.6 billion to expand its Bitcoin holdings.
MicroStrategy's market capitalization has now surpassed $100 billion, dominating U.S. trading volume on Wednesday night.
In addition, smaller firms like Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) are joining the trend, reportedly allocating $1 million to Bitcoin for their corporate treasuries. 
The unprecedented success of Bitcoin ETFs signals a growing mainstream acceptance of cryptocurrencies. 
BlackRock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>) and Fidelity are among the 12 issuers contributing to the $100 billion milestone, with analysts pointing to these funds as a significant factor in Bitcoin&#8217;s recent rally.
Eric Balchunas, a senior ETF analyst at Bloomberg, noted that December 31 could be an optimal time to submit applications for new crypto ETFs, including one linked to Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>). 
Meanwhile, aggressive buying of options for March and June indicates long-term bullish sentiment among investors.
As Bitcoin approaches the $100,000 psychological milestone, the market is expected to remain buoyant, supported by easing monetary policies and <a href="https://www.benzinga.com/news/events/24/11/42078359/blackrocks-head-of-digital-assets-says-ibit-spot-bitcoin-etf-options-blow-past-1-billion-in-trading-volume">sustained institutional demand.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42096519/bitcoin-to-reach-190000-this-cycle-michael-terpin-of-transform-group-says">Bitcoin To Reach $190,000 This Cycle, Michael Terpin Of Transform Ventures Says</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$HBAR

$SOL

$XRP

ACXP

MSTR

Bitcoin Hits New All-Time High Above $98,000 As Spot ETFs Crack $100 Billion Net Asset Value Milestone

Northland Capital Markets analyst Mike Grondahl maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and raises the price target from $20 to $24.

Northland Capital Markets Maintains Outperform on Universal Technical, Raises Price Target to $24

Northland Capital Markets analyst Nehal Chokshi reiterates Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Market Perform and raises the price target from $350 to $370.

Reiteration

Northland Capital Markets Reiterates Market Perform on Palo Alto Networks, Raises Price Target to $370

Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of an underwritten public offering of 44,964,045 shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,235,955 shares of its common stock, and in either case, accompanying Series A warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.0680 per share of common stock and Series B warrants to purchase 23,600,000 shares of its common stock at an exercise price of $1.3350 per share of common stock, at a combined public offering price of $0.89 per share of common stock and accompanying Series A and Series B warrants (or $0.8899 per pre-funded warrant and accompanying Series A and Series B warrants). All of the securities being sold in the offering are being sold by Verrica. The offering is expected to close on November 22, 2024, subject to the satisfaction of customary closing conditions. Verrica also granted the underwriter an option for a period of 30 days to purchase up to 7,080,000 additional shares of the Company's common stock and/or Series A warrants to purchase up to 3,540,000 additional shares of its common stock and Series B warrants to purchase up to 3,540,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Financing

Offerings

VRCA

Verrica Pharmaceuticals Priced Its Underwritten Public Offering Of $42M At A Combined Public Offering Price Of $0.89/Share And Accompanying Series A And Series B Warrants

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) with a Buy and maintains $9 price target.

IVVD

D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target

JMP Securities analyst Trevor Walsh maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Market Outperform and raises the price target from $380 to $415.

JMP Securities Maintains Market Outperform on Palo Alto Networks, Raises Price Target to $415

AMAT

Applied Materials Introduces MAX OLED Solution, A Patented OLED Pixel Architecture And Revolutionary Display Manufacturing Technology

Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) sees FY2025 sales of $2.800 billion-2.830 billion vs $2.85 billion estimate.

Guidance

VSTS

Vestis Sees FY2025 Sales $2.800B-$2.830B vs $2.85B Est

Government

Contracts

ZENA

ZenaTech Has Signed Blue Unmanned Aerial Systems And US National Defense Authorization Act Compliant Partner Agreements For Its Supply Chain To Sell Its ZenaDrone 1000 AI Drone Solutions To US Defense Branches And To NATO Forces

Fiscal 2025 Outlook
As previously announced, CPI's outlook for fiscal 2025 with regard to revenue, net income, Adjusted EBITDA and Adjusted EBITDA Margin is as follows:
<ul>
<li>Revenue in the range of $2.48 billion to $2.58 billion</li>
<li>Net income in the range of $97 million to $113 million</li>
<li>Adjusted EBITDA(1) in the range of $347 million to $377 million</li>
<li>Adjusted EBITDA Margin(1) in the range of 14.0% to 14.6%</li>
</ul>

ROAD

Construction Partners Now Expects FY25 Revenue Of $2.48B-$2.58B (From $2.42B - $2.52B) Vs. Est $2.48B

He will continue to serve as CFO until December 31, 2024 to ensure a smooth transition.
Shyft's Board of Directors is commencing a comprehensive search for a new CFO, supported by a leading, independent executive search firm. The Company is considering both internal and external succession candidates.

Management

SHYF

Shyft Group Says Jon Douyard Has Resigned As CFO To Pursue Another Professional Opportunity Outside The Industry

WIIM

Conduit Pharmaceuticals shares are trading higher after the company announced that the Japan Patent Office granted a composition of matter patent for its lead asset, AZD1656.

This approval follows the recent patent grant in Australia, highlighting Conduit's continued progress in safeguarding its intellectual property portfolio for future out-licensing opportunities.

Conduit Pharmaceuticals Says Japan Patent Office Granted Approval Of A Composition Of Matter Patent Application For Lead Asset AZD1656

Telsey Advisory Group analyst Joseph Feldman maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and lowers the price target from $195 to $150.

Telsey Advisory Group Maintains Outperform on Target, Lowers Price Target to $150

GXAI

Gaxos.ai Announced That The Company Has Integrated Suno AI And Elevenlabs Into Their Artificial Intelligence Solution For Game Developers And Publishers, Gaxos Labs

IDXX

IDEXX Names Andrew Emerson To Serve As Next CFO, Effective March 1, 2025; Brian McKeon To Retire In June 2025

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and raises the price target from $165 to $190.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Raises Price Target to $190

The latest update is out from Better For You Wellness (BFYW). Better For You Wellness, Inc., a Nevada-based corporation, has recently elevated Step...

Better For You Wellness Announces COO Leadership Update

The latest update is out from Better For You Wellness (BFYW). In a move to address deferred compensation, a company has converted owed amounts into...

Better For You Wellness Converts Executive Deferred Pay into Equity

An update from Better For You Wellness (BFYW) is now available. Better For You Wellness, Inc. has disseminated a press release with important busin...

Better For You Wellness Issues Investor Update Warning

Better For You Wellness (BFYW) just unveiled an announcement. Better For You Wellness, Inc. has released a press release on March 25, 2024, deliver...

Better For You Wellness Provides Business Update Preview

Better For You Wellness (BFYW) has issued an update. Better For You Wellness, Inc. has expanded its business by acquiring assets from The Ideation ...

Comments

Better For You Wellness

Better For You Wellness (BFYW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga